<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419195</url>
  </required_header>
  <id_info>
    <org_study_id>17-0356</org_study_id>
    <nct_id>NCT03419195</nct_id>
  </id_info>
  <brief_title>Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex</brief_title>
  <official_title>Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Eastern Colorado Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will define the relationship of cardiac, vascular function and skeletal muscle&#xD;
      blood flow (individually and together) to cardiovascular exercise capacity in in men and&#xD;
      women with and without type 2 diabetes (T2DM). Identification of differences in the effects&#xD;
      of exercise training on the integrated cardiovascular system and metabolism in men and women&#xD;
      with and without T2DM will reveal specific adaptive responses to exercise.This study will&#xD;
      evaluate &amp; compare exercise function in a total of 60 subjects from the Denver area (30&#xD;
      people with T2DM and 30 overweight control subjects).&#xD;
&#xD;
      Specific Aim 1: To test the hypothesis that the integration of cardiac function,&#xD;
      macrovascular function, and microvascular function is impaired in T2D and correlates with&#xD;
      cardiovascular exercise capacity (CVEC) impairment.&#xD;
&#xD;
      Specific Aim 2: To test the hypothesis that exercise training will elicit adaptive responses&#xD;
      in cardiac and vascular function, muscle perfusion and metabolism with differences by T2D&#xD;
      status.&#xD;
&#xD;
      Differences between the exercise responses in people with T2DM and healthy people will help&#xD;
      further identify the disease process of T2DM and direct future research of treatments and&#xD;
      interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well established that functional exercise capacity and peak oxygen uptake (VO2) are&#xD;
      reduced in patients with type 2 diabetes mellitus (T2DM) compared with healthy counterparts.&#xD;
      The mechanisms underlying the exercise deficit in T2DM remain largely unknown, but previous&#xD;
      work has suggested that reduced exercise blood flow and impaired submaximal VO2 may be&#xD;
      contributing factors. Both of these findings are consistent with a peripheral impairment of&#xD;
      skeletal muscle oxygen delivery, oxygen utilization, or both. Indeed, dysfunction of skeletal&#xD;
      muscle metabolism plays a key role in the pathophysiology of T2DM, and considerable work has&#xD;
      described abnormalities of oxidative function in the skeletal muscle of people with T2DM.&#xD;
      Given this, it is likely that the causes of exercise intolerance in T2DM may relate to&#xD;
      specific defects at the level of the skeletal muscle, particularly given that skeletal muscle&#xD;
      blood flow and oxidative capacity are impaired in diabetes. However, to the knowledge of the&#xD;
      investigators, no one has related these peripheral muscle abnormalities to the diminished&#xD;
      exercise function in this patient group.&#xD;
&#xD;
      The overarching hypothesis for the proposed research is that impaired CVEC in T2DM is the&#xD;
      result of preclinical cardiac, vascular dysfunction and skeletal muscle perfusion&#xD;
      abnormalities. Exercise training will improve CVEC and will reveal specific reversible&#xD;
      therapeutic aspects of this pathology. The investigators will first determine the impairments&#xD;
      and then evaluate responses to an established cardiac rehabilitation exercise training&#xD;
      program, established to improve fitness in people with and without diabetes. Given the&#xD;
      greater CVEC abnormalities observed in women, sex differences will be evaluated for each aim.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak oxygen consumption (VO2peak)</measure>
    <time_frame>Through study completion, approximately 4 months</time_frame>
    <description>Subjects' peak oxygen consumption will be tested on a stationary bike before and after 3 months of exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Through study completion, approximately 4 months</time_frame>
    <description>The investigators will evaluate the changes in insulin sensitivity utilizing a euglycemic insulin clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscular mitochondrial function</measure>
    <time_frame>Through study completion, approximately 4 months</time_frame>
    <description>The investigators will examine mitochondrial function using magnetic resistance (MR) spectroscopy during single leg calf exercise</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Healthy</condition>
  <condition>Overweight</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C &lt;9%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy overweight controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiovascular exercise training</intervention_name>
    <description>Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.</description>
    <arm_group_label>Healthy overweight controls</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <other_name>Exercise Training</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women with and without type 2 diabetes&#xD;
&#xD;
          -  BMI 25-40&#xD;
&#xD;
          -  Sedentary subjects not participating in a regular exercise program (&lt;one bout of&#xD;
             exercise/week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled hypertension: disease systolic blood pressure (SBP) &gt; 150, diastolic&#xD;
             blood pressure (DBP)&gt; 110&#xD;
&#xD;
          -  Obstructive pulmonary disease or asthma&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Physical impairment that would limit exercise ability&#xD;
&#xD;
          -  Subjects taking beta blockers, calcium channel blockers, insulin, or&#xD;
             Thiazolidinediones (TZD)&#xD;
&#xD;
          -  Current or past smoking within the last 1 years&#xD;
&#xD;
          -  Current tobacco use&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Control HbA1c &gt; 5.7, T2DM HbA1c &gt; 9&#xD;
&#xD;
          -  Pregnant, nursing or hormonal therapy (other than contraceptives)&#xD;
&#xD;
          -  Peri or post-menopausal women&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Hepatic or renal disease.&#xD;
&#xD;
          -  Peptic ulcer disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Regensteiner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deirdre Rafferty, MS</last_name>
    <phone>720-848-6688</phone>
    <email>deirdre.rafferty@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judy Regensteiner, PhD</last_name>
    <phone>303-724-2247</phone>
    <email>judy.regensteiner@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre Rafferty, MS</last_name>
      <phone>720-848-6688</phone>
      <email>deirdre.rafferty@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Chapman, BS</last_name>
      <phone>720-848-6690</phone>
      <email>kristina.chapman@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Judy Regensteiner, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Reusch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Overweight</keyword>
  <keyword>Exercise Training</keyword>
  <keyword>Exercise Impairment</keyword>
  <keyword>Healthy Control</keyword>
  <keyword>Veteran</keyword>
  <keyword>Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03419195/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

